Gelesis Holdings, Inc.
GLSHDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001805087
Gelesis Holdings, Inc. was delisted in 2023; its insiders filed their last Form 4 on Sep 21, 2023; no institution reported holding it in 13F filings for Q3 2023; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Gelesis Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Gelesis Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| PureTech Health LLC | 10% Owner | – | Sep 21, 2023 | 0 |
| PureTech Health plc | 10% Owner | – | Sep 21, 2023 | 0 |
| Kucherlapati Raju S | Director | 190,264 | Nov 22, 2022 | 0 |
| Sannino Alessandro | Lead Project Scientist | 207,143 | Jun 13, 2022 | 0 |
| Chiquette Elaine | Chief Scientific Officer | 263,079 | Jun 10, 2022 | 0 |
| Bauerlein Alison | Director | 51,095 | May 9, 2022 | 0 |
| Maltz Elliot | Chief Financial Officer | 431,975 | May 9, 2022 | 0 |
| Zohar Yishai | President & CEO | 1,814,818 | May 9, 2022 | 0 |
| Abraham David | General Counsel | 256,437 | May 9, 2022 | 0 |
| Fonteyne Paul R. | Director | 53,832 | May 9, 2022 | 0 |
| Cavanaugh Kathryn | Director | 61,639 | May 9, 2022 | 0 |
| Christopher Clayton | Director | 510,768 | May 9, 2022 | 0 |
| Leider Harry L. | Chief Medical Officer | 314,090 | May 9, 2022 | 0 |
| Wildman Jane | Director | 50,182 | May 9, 2022 | 0 |
| Pass David A. | Chief Operating Officer | 483,219 | May 9, 2022 | 0 |
| Perks Dominic | Director | 49,270 | May 9, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2023 (view filing)4:30 PM ET | Sep 20 | 1 day | PureTech Health LLC and 1 other10% Owner | PPurchase | +30.4M | – | – | – | DerivativePrice outlier |
| Jun 14, 2023 (view filing)4:30 PM ET | Jun 12 | 2 days | PureTech Health LLC and 1 other10% Owner | PPurchase | +223.9M | – | – | – | DerivativePrice outlier |
| May 31, 2023 (view filing)5:30 PM ET | May 26 | 5 days | PureTech Health LLC and 1 other10% Owner | PPurchase | +67.8M | – | – | –43.1M after | Derivative2 lotsPrice outlier |
| May 3, 2023 (view filing)4:30 PM ET | May 1 | 2 days | PureTech Health LLC and 1 other10% Owner | PPurchase | +344.5M | $225,637.55 | +$29.0T | –192.3M after | Derivative4 lotsPrice outlier |
| Nov 22, 2022 (view filing)6:20 PM ET | Nov 18-21 | 4 days | Kucherlapati Raju SDirector | PPurchase | +100.0K | $0.4452 | +$44.5K | +110.8%190.3K after | 2 lots |
| Jun 17, 2022 (view filing) | Jun 15 | 2 days | Kucherlapati Raju SDirector | PPurchase | +24.6K | $1.95 | +$48.0K | +37.5%90.3K after | |
| Jan 19, 2022 (view filing) | Jan 14 | 5 days | Kucherlapati Raju SDirector | PPurchase | +15.0K | $6.67 | +$100.0K | New position15.0K after |